HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years.

Abstract
Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT. Conditioning was performed with total body irradiation (TBI) and cyclophosphamide. The 9-year overall survival (OS) was similar in the HDT and conventional chemotherapy groups (76% and 80%, respectively). The 9-year progression-free survival (PFS) was higher in the ASCT than the chemotherapy group (64% vs 39%; P = .004). A PFS plateau was observed in the HDT group after 7 years. On multivariate analysis, OS and PFS were independently affected by the per-formance status score, the number of nodal areas involved, and the treatment group. Secondary malignancies were more frequent in the HDT than in the chemotherapy group (6 secondary myelodysplastic syndrome/acute myeloid leukemia and 6 second solid tumor cancers vs 1 acute myeloid leukemia, P = .01). The occurrence of a PFS plateau suggests that a subgroup of patients might have their FL cured by ASCT. However, the increased rate of secondary malignancies may discourage the use of purged ASCT in combination with TBI as first-line treatment for FL. This trial has been registered with ClinicalTrials.gov under identifier NCT00696735.
AuthorsEmmanuel Gyan, Charles Foussard, Philippe Bertrand, Patrick Michenet, Steven Le Gouill, Christian Berthou, Hervé Maisonneuve, Vincent Delwail, Rémi Gressin, Philippe Quittet, Jean-Pierre Vilque, Bernard Desablens, Jérôme Jaubert, Jean-François Ramée, Nina Arakelyan, Antoine Thyss, Cécile Moluçon-Chabrot, Roselyne Delépine, Noël Milpied, Philippe Colombat, Eric Deconinck, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS)
JournalBlood (Blood) Vol. 113 Issue 5 Pg. 995-1001 (Jan 29 2009) ISSN: 1528-0020 [Electronic] United States
PMID18955565 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Myeloablative Agonists
  • Cyclophosphamide
Topics
  • Adolescent
  • Adult
  • Bone Marrow Purging
  • Cyclophosphamide (administration & dosage)
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Immunotherapy (methods)
  • Lymphoma, Follicular (mortality, therapy)
  • Male
  • Middle Aged
  • Myeloablative Agonists (administration & dosage)
  • Neoplasms, Second Primary (mortality)
  • Stem Cell Transplantation
  • Survival Rate
  • Transplantation Conditioning
  • Transplantation, Autologous
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: